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Abstract
Objective—Limited data exist on the rates of pelvic organ prolapse procedures utilizing mesh.
The objective of this study was to examine trends in vaginal mesh prolapse procedures (VM),
abdominal sacrocolpopexy (ASC) and minimally-invasive sacrocolpopexy (MISC) from 2005–
2010.
Study Design—We utilized de-identified, adjudicated healthcare claims data from across the
United States from 2005–2010. Among women ≥18 years, we identified all mesh prolapse
procedures based on CPT codes (57267 for VM, 57280 for ASC and 57425 for MISC). VM
procedures included all vaginal prolapse surgeries in which mesh was placed, whether in the
anterior, apical or posterior compartment. We estimated rates per 100,000 person-years
(100,000py) and 95% confidence intervals (95% CI).
Results—During 78.5 million person-years of observation, we identified 60,152 mesh prolapse
procedures, for a rate of 76.0 per 100,000py 100,000py (95% CI: 73.6, 78.5). Overall, VM
comprised 74.9% of these surgeries for an overall rate of 56.9 per 100,000py (95% CI: 55.0, 58.9).
Rates of ASC and MISC were considerably lower at 12.0 per 100,000py (95% CI: 11.6, 12.5) and
9.5 per 100,000py (95% CI: 9.2, 9.9), respectively. Among sacrocolpopexies, ASC was more
common than MISC in 2005–2007; however, since 2007, the rate of MISC has increased while the
rate of ASC has decreased. Regarding trends by age, VM was considerably more common than
sacrocolpopexies at all ages, and ASC was more common than MISC in women over 50 years.
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Conclusions—From 2005 to 2010, the rate of mesh prolapse procedures has increased, with
vaginal mesh surgeries constituting the vast majority.
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INTRODUCTION
The recent FDA safety communication regarding vaginal mesh for pelvic organ prolapse has
drawn attention to the surgical management of this highly prevalent condition.1 In the July
2011 update on the original 2008 public health notification2, the FDA stated that “based on
an updated analysis of adverse events reported to the FDA and complications described in
the scientific literature, the FDA identified surgical mesh for transvaginal repair of POP as
an area of continuing serious concern.”1 The American Congress of Obstetricians and
Gynecologists (ACOG) and the American Urogynecologic Society (AUGS) have recognized
the critical importance of complications such as mesh exposure, erosion and contracture, and
the symptoms associated with these complications.3
The first mesh “kits” to aid in the insertion of vaginal synthetic graft material for prolapse
were cleared by the FDA in 2004 and marketed by American Medical Systems (AMS) under
the names Apogee™ and Perigee™ Systems.4, 5 Since then, there has been an influx of new
prolapse mesh devices introduced in the United States.6 Sales data from manufacturers
indicate that 300,000 women underwent pelvic organ prolapse surgery in 2010.6 Of these,
one-third utilized mesh (~100,000), and three-quarters of these mesh procedures were
transvaginal surgeries. Thus, approximately, 75,000 procedures involved transvaginal
placement of mesh. Despite these estimates, population-based estimates of vaginal and
abdominal mesh prolapse surgeries are extremely limited. Furthermore, utilization of mesh
for prolapse repair categorized by age and region is lacking.
Several studies have evaluated national trends in prolapse surgeries overall7–10, but these
estimates provide limited information regarding mesh prolapse procedures specifically. One
reason is that International Classification of Diseases, 9th Revision, Clinical Modification
(ICD-9-CM) codes for prolapse graft materials (i.e. codes 70.53, 70.54, 70.55, 70.94 and
70.95) were not introduced until 2007.11 Another limitation is that ICD-9-CM procedure
codes, which are utilized by a majority of national databases, do not incorporate the more
specific Current Procedural Terminology (CPT) codes. Because of these limitations, the
rates of specific mesh procedures have not been reported, and the impact on rates of
transvaginal mesh procedures after the two recent FDA notifications in 2008 and 2011 is
relatively unknown. It is critical to understand whether the FDA safety notifications have
translated into changes in the rates of transvaginal mesh procedures.
Given the knowledge gaps in the existing literature, we sought to use the more informative
CPT codes in a population-based analysis to estimate trends in prolapse mesh procedures
from 2005 – 2010. Furthermore, we wanted to estimate the rates of specific prolapse
procedures, such as vaginal mesh procedures (VM), abdominal sacral colopopexy (ASC)
and minimally-invasive sacrocolpopexy (MISC) and to estimate the trends in these surgeries
based on age and region of the U.S.
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This analysis is based on Thomson Reuters’ MarketScan® Commercial Claims and
Encounters (CC&E) database and Medicare Supplemental and Coordination of Benefits
database from 2005 – 2010 (copyright © 2011 Thomson Healthcare Incorporated Inc. All
rights reserved).12 These data represent the medical encounters of individuals with
employment-based insurance including spouses, dependents, and retirees. Specifically, the
databases contain de-identified, individual-level inpatient, outpatient, and pharmacy claims
as well as detailed enrollment data from approximately 100 payers in the United States.
Claims and enrollment data are validated to ensure completeness, accuracy, and reliability.
Although the data are de-identified, unique individuals can be followed over time using
encrypted identification numbers. The databases contain adjudicated, paid claims for
approximately 28.3 million individuals in 2005, increasing to 48.8 million in 2010. Of note,
in 2010, 55.3% of the U.S. population had employment-based insurance.13 This study was
determined to be exempt from further review by the Institutional Review Board at the
University of North Carolina at Chapel Hill.
Pelvic Organ Prolapse Mesh Surgery Rates
The study population included all women aged 18 years or older from 2005 – 2010. We
utilized CPT codes to identify any prolapse procedures involving mesh placement. A vaginal
mesh procedure was defined by the CPT code 57267 (insertion of mesh or other prosthesis
for repair of pelvic floor defect, each site, vaginal approach). Because this code is listed in
addition to CPT code(s) for the primary procedure(s), we defined a vaginal mesh procedure
if CPT 57267 was listed at least once on a specific surgery date. For example, if mesh was
placed in both the anterior and posterior compartment and CPT 57267 was listed twice, this
surgery would be counted as a single VM procedure. We chose to evaluate trends starting in
2005 because the CPT code 57267 was released on January 1, 2005.14 We opted to use CPT
codes instead of ICD-9-CM codes, as ICD-9-CM vaginal mesh codes were not introduced
until 2007.11 For sacrocolpopexies, ASC were identified using CPT 57280, which indicates
“colpopexy, abdominal approach.” Minimally-invasive sacrocolpopexies, MISC, were
defined by CPT 57425, a code that was released in 2004. MISC represents both laparoscopic
and robotic-assisted laparoscopic sacrocolpopexies as CPT codes distinguishing these two
types of surgeries do not exist.
Rates were calculated by dividing the total number of surgeries in each category (VM, ASC
and MISC) by the total person-time at risk. In order to calculate person-time at risk, we
summed all periods of time when eligible women were enrolled in a health plan that
contributed to the database.
We also evaluated common concurrent procedures with VM, ASC and MISC. Specifically,
we evaluated concomitant sling, CPT 57288, as well as concomitant hysterectomy. We
evaluated the type of hysterectomy (total versus supracervical) based on CPT codes. Total
hysterectomy included total abdominal (CPT 58150, 58152, 58200, 58210), total vaginal
(CPT 58260, 58262, 58263, 58267, 58270, 58275, 58280, 58285, 58290, 58291, 58292,
58293, 58294), and total laparoscopic which also included laparoscopic assisted vaginal
hysterectomy (CPT 58545, 58546, 58548, 58550, 58552, 58553, 58554, 58570, 58571,
58572, 58573). Supracervical hysterectomies included both abdominal supracervical (CPT
58180) and laparoscopic supracervical (CPT 58541, 58542, 58543, 58544).
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We estimated the rate of any prolapse mesh surgery overall, as well as procedure-specific
rates for VM, ASC and MISC. In addition, we estimated the procedure and calendar-year,
procedure and location (inpatient vs outpatient), procedure and age, and procedure and
region specific rates for prolapse mesh surgery. We estimated 95% confidence intervals
(CIs) based on the Poisson distribution. Rates and CIs are reported per 100,000 person-years
(100,000py).
In order to adjust for differences in the age distribution over calendar time and across
regions, we estimated region-specific and calendar-year specific rates using Poisson
regression while adjusting for age using 15 categorical variables (18–24, 25–29, 30–34, 35–
39, 40–44, 45–49, 50–54, 55–59, 60–64, 65–69, 70–74, 75–79, 80–84, 85–89, 90+). Wald
chi-square statistics were used to test the significance of independent predictors with a two-
sided alpha=0.05. All confidence intervals were estimated and statistical tests were
conducted using Poisson regression with the dispersion parameter empirically estimated by
the Pearson chi-square divided by the degrees of freedom to account for overdispersion.
Analyses were performed using SAS, v9.2 (SAS Institute, Cary, NC).
RESULTS
From 2005 – 2010, women aged 18 years and older contributed a total of 78,496,836
person-years. Among these women, there were 60,152 pelvic organ prolapse procedures
which involved the use of mesh. Table 1 lists the person-time contribution for the population
at-risk, divided by calendar year, age group (18–29, 30–39, 40–49, 50–59, 60–69, 70–79,
80+ years), and region of the U.S. Furthermore, Table 1 describes the overall number of
prolapse procedures with mesh, as well as the specific type of surgery, whether VM, ASC or
MISC.
The overall rate of any prolapse surgery with mesh was 76.0 per 100,000py (95% CI 73.6,
78.5) (Table 2). VM comprised 74.9% of these surgeries for an overall rate of 56.9 per
100,000py (95% CI: 55.0, 58.9). Rates of ASC and MISC were considerably lower at 12.0
per 100,000py (95% CI: 11.6, 12.5) and 9.5 per 100,000py (95% CI: 9.2, 9.9), respectively
(Table 2). While approximately half of the VM and MISC procedures were performed on an
outpatient basis, a majority of the ASC procedures were inpatient surgeries (Table 2).
Regarding the trend for the total number of prolapse mesh procedures from 2005–2010,
there was a significant increase from 53.5 per 100,000py (95% CI 49.4, 57.9) in 2005 to
83.7 per 100,000py (95% CI 77.3, 90.5) in 2010 (p<.0001) (Figure 1). There was also a
significant increase for VM procedures from 36.7 to 60.8 per 100,000py (p<.0001) (Table 2;
Figure 1). For VM, the rate appears to increase from 2005 to 2008 and then level off from
2008 to 2010. Among sacrocolpopexies, the rate of ASC significantly decreased from 14.8
per 100,000py (95% CI 13.5, 16.2) in 2005 to 9.9 per 100,000py (95% CI 9.1, 10.8) in 2010
(p<.0001). In contrast, the rate of MISC significantly increased from 4.3 to 15.9 per
100,000py (p<.0001). By 2010, the rate of MISC was higher than that of ASC (Table 2).
VM was the most common type of prolapse mesh surgery with age-specific rates higher than
ASC and MISC for all age cohorts (Table 2, Figure 2). The age-specific rate for VM was
highest in women aged 70–79 years, while the rates of ASC and MISC were highest in
women aged 60–69 years (Table 2).
When evaluating trends by region, Figure 3 depicts the age-specific rates for any prolapse
mesh procedure from 2005–2010 by region of the U.S. This figure illustrates that all regions
had significantly higher rates of prolapse mesh surgeries compared to the Northeast, after
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adjusting for age (p<.0001). Furthermore, the rates were highest in the South compared to
the other regions of the U.S (Table 2).
We also wanted to describe common concurrent procedures that occurred with the use of
mesh for prolapse. A concomitant sling occurred in 39.9% (n=24,024) and a concurrent
hysterectomy in 27.2% (n=16,363) of mesh prolapse procedures. Among hysterectomies,
14.6% (n=2,385) were supracervical.
COMMENT
In this population-based analysis of more than 60,000 pelvic organ prolapse procedures
utilizing mesh, vaginal mesh represented the majority (74.9%) of surgeries. From 2005 to
2010, there has been a significant increase in prolapse mesh procedures, largely due to the
increase in VM, since rates of sacrocolpopexies (both ASC and MISC) remained relatively
low. Interestingly, the rate of ASC declined over this time period while the rate of MISC
increased. As for trends based on age, VM was the most common procedure across all age
groups. Despite the initial FDA public health notification in October 2008,2 we did not see
evidence of a dramatic decrease in the rate of VM procedures after 2008 but this rate did
appear to level off from 2008 – 2010.
Our CPT-based approach to describe mesh use during prolapse surgery is novel, as prior
literature is limited. In 2010, the FDA estimated that of the 300,000 prolapse surgeries
performed annually, one-third utilized mesh grafts.6 Our finding that 74.9% of the mesh
procedures were VM mirrors industry estimates that three-quarters of mesh procedures are
transvaginal. These data confirm the popularity of these surgeries in current practice.
The high rate of VM procedures further emphasizes the importance of potentially serious
complications of these procedures. The FDA July 2011 update stated that there were 1,503
reported complications associated with surgical mesh devices for prolapse from January 1,
2008 through December 31, 2010.1 The most common complications included “mesh
erosion through the vagina (also called exposure, extrusion or protrusion), pain, infection,
bleeding, pain during sexual intercourse (dyspareunia), organ perforation, and urinary
problems. There were also reports of recurrent prolapse, neuro-muscular problems, vaginal
scarring/shrinkage, and emotional problems”.1 Unfortunately, many of these complications
required additional interventions, and anecdotally, many urogynecologists are witnessing a
dramatic increase in the number of patients with mesh complications in their practices.
While the existing literature suggests that there may be a role for mesh augmentation in the
anterior compartment for improved anatomic success 3, 6, 15, 16, the FDA stated that it is not
clear that that mesh augmentation is more effective than compared to native tissue
repairs.1, 6 In their joint committee opinion, ACOG and AUGS recommended that mesh
augmentation be reserved for high-risk individuals in whom the benefit of mesh placement
outweighs the potential risks.3 While the initial FDA notification in 2008 did not have a
dramatic impact on VM rates, it will be important to monitor the impact of the July 2011
update on rates of VM procedures in the coming years.
In addition to an increase in VM procedures from 2005 to 2010, our data shows an increase
in the MISC rate and a decrease in ASC rate over the study period. Because of the limited
detail of CPT codes in current use, we are unable to distinguish between laparoscopic and
robotic-assisted sacrocolpopexies, and we cannot definitively state what proportion of MISC
is due to each of these approaches. Jones et al.9 showed that laparoscopic prolapse surgeries
increased among inpatients from 1979 to 2006, and Bradley et al.10 reported that minimally-
invasive inpatient prolapse procedures increased from 4.8% in 1998 to 9.4% in 2007. While
the laparoscopic sacrocolpopexy was first described in 1994 17, the robotic-assisted
approached was first reported in 2004.18, 19 In 2005, the da Vinci Surgical System (Intuitive
FUNK et al. Page 5










Surgical, Inc., Sunnyvale, CA) was approved by the FDA for use in gynecology.20 Given
this timeline, we postulate the greater proportion of the increase in the MISC rate may be
secondary to an increase in the number of robotic-assisted sacrocolpopexies.
In our study, we found that a total hysterectomy (TAH) was more common than a
supracervical hysterectomy (SCH) for both ASC and MISC. The literature is conflicting
regarding the relationship of type of hysterectomy and the risk of mesh erosion.(22) Several
studies suggest that there may be no difference between the risk of mesh erosion after ASC
between TAH and SCH.21, 22 However, a large randomized multi-centered study found an
increased risk of mesh or suture erosion with ASC with concomitant TAH (14%) compared
to those with a prior hysterectomy (4%).23 Furthermore, two studies which assessed robotic-
assisted MISC found no erosions among subjects who had concomitant SCH.24, 25 These
data suggest concurrent SCH may decrease the risk of mesh erosion following a
sacrocolpopexy. However, minimally invasive SCH is not without its trade-offs, as there is
the need for continued cervical cancer screening and the risk of unanticipated premalignant
or malignant uterine pathology in a morcellated SCH specimen,.25–27 Further research and
education regarding hysterectomy choice and ASC and MISC is warranted.
The largest proportion of mesh prolapse surgeries in our study was performed in women
aged 60–69 years. This age range is similar to that of prior studies investigating inpatient
prolapse surgery trends in the U.S, as most procedures were performed in women aged 60–
79 years.10, 28 Prior investigations have also shown the mean age of women undergoing both
inpatient and outpatient prolapse surgery in the U.S. has increased over the last decade.8, 9
Regional trends have consistently shown that the South has the highest rates of prolapse
surgery, though this is largely unexplained.9, 10, 28 This trend could potentially be related
several factors: the increased tendency of physicians in the South to perform surgery for
prolapse, a higher prevalence of disease in the South, or greater preference of surgery as a
treatment option for prolapse among Southern women. These factors have not been
thoroughly investigated or well explored.
In this study, we present data regarding the rates of prolapse procedures which involve the
use of mesh. The strengths of this study include the use of a population-based database of
adjudicated healthcare claims, which provides an exceptionally large cohort to evaluate.
Furthermore, the utilization of CPT versus ICD-9 codes allowed us to evaluate specific
prolapse procedures - i.e. VM vs ASC vs MISC, as well as the whether these procedures
were performed on an inpatient or outpatient basis. Lastly, we evaluated trends starting in
2005, as the CPT vaginal mesh codes were introduced that year. Evaluation of prolapse
mesh procedures prior to 2005 may not be particularly accurate as specific codes were not
available.
Regarding limitations, it is possible that some VM procedures were not appropriately coded
in 2005, as CPT code 57267 was introduced that year; however, the significant upward trend
in VM rates suggests that there has likely been an increase in the use of these procedures.
Another factor is that we did not have details regarding the surgical procedure in terms of
the type of mesh utilized as well as the method in which mesh was placed. For MISC, the
CPT code 57425 for laparoscopic colpopexy could also represent laparoscopic uterosacral
ligament suspensions; thus it is possible that we may have slightly overestimated the rate of
sacral colpopexies utilizing mesh. In addition, we were unable to evaluate certain
demographic or clinical factors, such race, body mass index (BMI), indication for surgery
(i.e. primary prolapse surgery or surgery for recurrent prolapse), or stage of prolapse. Lastly,
our database included only those with employer-based insurance, and thus our results may
not be generalizable to those without other types of insurance or self-pay patients.
Fortunately, with the Medicare supplemental database, we were able to evaluate older
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women who had employer-based insurance and then transitioned into Medicare at 65 years
of age.
In conclusion, transvaginal mesh procedures comprised 75% of all prolapse mesh surgeries,
and VM was the most common mesh procedure across all age groups. Although rates of
vaginal mesh procedures were significantly higher than abdominal and minimally-invasive
sacrocolpopexies, the rate of MISC increased while that of the ASC decreased from 2005 to
2010. Although we did not see a dramatic decrease in the rate of VM procedures after the
initial FDA public health notification in 2008, the rate of VM appeared to level off from
2008–2010. It will be important to evaluate the impact of the July 2011 FDA notification, as
this statement highlighted serious complications after transvaginal mesh prolapse surgery
more emphatically than the 2008 statement. Beyond evaluating trends in surgery rates,
future studies should strive for rigorous, comparative effectiveness studies that incorporate
patient-centered outcome measures as well as long-term, population-based data regarding
complications of vaginal mesh. Despite the popularity of VM procedures, population-based
data regarding the rates of repeat surgery to manage complications such as mesh erosion/
exposure and mesh contracture are strikingly lacking.
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Figure 1. Annual rates of mesh prolapse procedures
Annual rates per 100,000 person-years for all mesh pelvic organ prolapse procedures,
vaginal mesh (VM), abdominal sacrocolpopexy (ASC), minimally invasive sacrocolpopexy
(MISC) from 2005–2010. Regarding the trend for the total number of prolapse mesh
procedures (All Mesh) over calendar time, there was a significant increase (p<.0001). There
was also a significant increase for VM procedures and MISC from 2005 to 2010 (p<.0001).
In contrast, there was a significant decrease in the rate of ASC over calendar year (p<.0001).
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Figure 2. Age-specific rates for mesh prolapse procedures
Age-specific rates per 100,000 person-years for vaginal mesh (VM), abdominal
sacrocolpopexy (ASC), minimally invasive sacrocolpopexy (MISC) performed from 2005–
2010,
FUNK et al. Page 11










Figure 3. Age-specific rates for mesh prolapse procedures by region of the U.S
Age-specific rates for prolapse mesh procedures performed from 2005–2010, stratified by
region of the United States. When evaluating regional differences in prolapse mesh surgery
rates after adjusting for age, all regions have significantly higher rates when compared to the
Northeast (p<.0001).
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